Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy

被引：0

作者：

Pepin, Abigail ^{[1
]}

Lee, Vivian ^{[2
]}

O'Brien, Sophia ^{[3
]}

Mulugeta, Philipose ^{[3
]}

Taunk, Neil K. ^{[1
]}

机构：

[1] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA

[2] Hosp Univ Penn, Dept Ophthalmol, Philadelphia, PA USA

[3] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA USA

来源：

PRACTICAL RADIATION ONCOLOGY | 2024年 / 14卷 / 04期

关键词：

SALIVARY; GLANDS;

D O I：

10.1016/j.prro.2024.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment options for patients with metastatic castration-resistant prostate cancer include use of radioligand therapy with 177LuPSMA-617. 177Lu-PSMA-617 is used to target prostate cancer cells selectively by targeting prostate specific membrane antigen (PSMA); however, PSMA is also expressed on lacrimal glands among other tissues. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 3 dry eye event with concomitant blepharitis after administration of 177Lu-PSMA-617. The patient was managed with neomycin-polymyxin-dexamethasone 3.5-10000-0.1 ophthalmic suspension, artificial tears, lubricating ointments, lid scrubs, and oral antihistamines. (c) 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

引用

页码：301 / 304

页数：4

共 50 条

[1] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
Ngoc, Christina Nguyen
Happel, Christian
Davis, Karen
Groener, Daniel
Mader, Nicolai
Mandel, Philipp
Tselis, Nikolaos
Gruenwald, Frank
Sabet, Amir
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
Rahbar, Kambiz
Boegemann, Martin
Ahmadzadehfar, Hojjat
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
[3] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
[4] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
Groener, Daniel
Baumgarten, Justus
Davis, Karen
Happel, Christian
Ngoc, Christina Nguyen
Wichert, Jennifer
Mader, Nicolai
Mandel, Philipp
Nikolaos, Tselis
Gruenwald, Frank
Sabet, Amir
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[5] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
Yadav, Madhav Prasad
Ballal, Sanjana
Tripathi, Madhavi
Bal, Chandrasekhal
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
[6] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Boegemann, Martin
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
[7] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
Jueptner, Michael
Marx, Marlies
Zuhayra, Maaz
Luetzen, Ulf
[J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
[8] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
Kambiz Rahbar
Hojjat Ahmadzadehfar
Martin Boegemann
[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
[9] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Mair, Christian
Warwitz, Boris
Fink, Katharina
Scarpa, Lorenza
Nilica, Bernhard
Maffey-Steffan, Johanna
Buxbaum, Sabine
Virgolini, Irene J.
[J]. ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
[10] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Christian Mair
Boris Warwitz
Katharina Fink
Lorenza Scarpa
Bernhard Nilica
Johanna Maffey-Steffan
Sabine Buxbaum
Irene J. Virgolini
[J]. Annals of Nuclear Medicine, 2018, 32 : 499 - 502

← 1 2 3 4 5 →